Rakuten and SBI contributed to the cancer therapy developer's series C round, which was closed with a $134m second tranche.
US-based oncology drug developer Rakuten Aspyrian has completed a $284m series C round featuring e-commerce firm Rakuten and financial services provider SBI Group.
The close of the round came through the provision of $134m of funding that was added to a $150m first tranche secured in August this year. The first close was led by Rakuten chief executive Hiroshi Mikitani, who is also Rakuten Aspyrian’s chairman.
Founded in 2015, Rakuten Aspyrian is working on cancer treatments based on its Photoimmunotherapy…
